Clinical and Epidemiological Study of EGFR Mutation and EML4-ALK Fusion Gene Among Indian Patients with Adenocarcinoma Lung
Not Applicable
- Conditions
- Health Condition 1: null- Non Small Cell Lung Cancer (NSCLC)
- Registration Number
- CTRI/2012/04/002589
- Lead Sponsor
- Pfizer India
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
Patients known as having an adenocarcinoma histology of NSCLC, already tested for EGFR mutational status and treated over the last 2 years will be considered for this study.
Exclusion Criteria
Non-adenocarcinoma histology of NSCLC
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of the prevalence of EGFR and EML4-ALK fusion in Indian NSCLC (adenocarcinoma) patient populationTimepoint: Single Time-point. As the study involves retrospective analysis of available slides/tissue blocks at trial sites, the collection of individual sample will be done at a single time-point and analysis also will be for a single time-point.
- Secondary Outcome Measures
Name Time Method To evaluate the association of EGFR and EML4-ALK fusion with clinical and pathologic parameters of NSCLC (adenocarcinoma) and patient characteristics <br/ ><br>Timepoint: Single Time-point